Patent(s) and the Corresponding Patented Drug(s) |
Top |
World Intellectual Property Organization (WIPO) |
Patent ID |
WO2014180165 |
Title |
Benzoisothiazole Compounds and Use In Preparation of Antipsychotic Drugs. |
Abstract |
Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D3 receptor, 5-HT1A receptor and 5-HT2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof. |
Applicant(s) |
Shanghai Inst Pharm Industry |
Representative Drug(s) |
D0Z9WY |
Drug Info
|
Ki = 0.058 nM |
Click to Show More |
[1] |
2
|
D0M1UF
|
Drug Info
|
Ki = 0.23 nM
|
[1] |
Patent ID |
WO2009019174 |
Title |
Benzoyl-Piperidine Derivatives As Dual Modulators of The 5-Ht2A and D3 Receptors. |
Abstract |
The present invention relates to compounds of the general Formula (I) wherein R1 and A are as defined in the specification as dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, their manufacture, pharmaceutical compositions containing them and their use as medicaments. Compounds of general Formula (I) have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment. |
Applicant(s) |
F. Hoffmann-La Roche Ag |
Representative Drug(s) |
D06RIO |
Drug Info
|
Ki = 4.88 nM |
Click to Show More |
[2] |
2
|
D02GTU
|
Drug Info
|
Ki = 6 nM
|
[2] |
3
|
D0J7SD
|
Drug Info
|
Ki = 8.65 nM
|
[2] |
4
|
D0FR1P
|
Drug Info
|
Ki = 34 nM
|
[2] |
Patent ID |
WO2007019083 |
Title |
Pyrimidine Compounds As Serotonin Receptor Modulators. |
Abstract |
Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases. |
Applicant(s) |
Janssen Pharmaceutica Nv |
Representative Drug(s) |
D00YGY |
Drug Info
|
Ki = 0.55 nM |
Click to Show More |
[2] |
2
|
D0B7NS
|
Drug Info
|
Ki = 4 nM
|
[2] |
3
|
D0P9VX
|
Drug Info
|
Ki = 4 nM
|
[2] |
4
|
D0U9UH
|
Drug Info
|
Ki = 11 nM
|
[2] |
5
|
D08DJY
|
Drug Info
|
Ki = 12.5 nM
|
[2] |
6
|
D0N2VA
|
Drug Info
|
Ki = 25 nM
|
[2] |
7
|
D0SE9K
|
Drug Info
|
Ki = 25 nM
|
[2] |
Patent ID |
WO2008042388 |
Title |
Pyrazole Derivatives As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Treatment of Disorders Related Thereto. |
Abstract |
Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D03IAB |
Drug Info
|
N.A. |
Click to Show More |
[2] |
2
|
D0DW6V
|
Drug Info
|
N.A.
|
[2] |
Patent ID |
WO2005012254 |
Title |
Diaryl and Arylheteroaryl Urea Derivatives As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Prophylaxis and Treatment of Disorders Related Therto. |
Abstract |
The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the prophylaxis or treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders and the like. The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0JT3F |
Drug Info
|
N.A. |
Click to Show More |
[2] |
2
|
D0ZF0Z
|
Drug Info
|
N.A.
|
[2] |
Patent ID |
WO2012175531 |
Title |
Method of Administration of 4-((1R,3S)-6-Chloro-3-Phenyl-Indan-1-Yl)-1,2,2-Trimethyl-Piperazine and The Salts Thereof In The Treatment of Schizophrenia. |
Abstract |
The present invention relates to 4-((1 R,3S)-6-chloro-3-phenyl-indan-1 -yl)-1,2,2-trimethyl- piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of diseases in the central nervous system in a once weekly dosing regime. |
Applicant(s) |
H. Lundbeck A / S |
Representative Drug(s) |
D0J4AZ |
Drug Info
|
Ki = 4.2 nM |
[2] |
Patent ID |
WO2010062323 |
Title |
Compositions of A 5-Ht2A Serotonin Receptor Modulator Useful for The Treatment of Disorders Related Thereto. |
Abstract |
The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0H8IH |
Drug Info
|
N.A. |
[2] |
Patent ID |
WO2006100519 |
Title |
Arylsulfonyl Benzofused Heterocycles As 5-Ht2A Antagonists. |
Abstract |
Compounds of formula (I): are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders. |
Applicant(s) |
Merck Sharp & Dohme Limited |
Patent ID |
WO2006097766 |
Title |
Arylsulfonyl Benzyl Ethers As 5-Ht2A Antagonists. |
Abstract |
Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders. |
Applicant(s) |
Merck Sharp & Dohme Limited |
Patent ID |
WO2001029008 |
Title |
Pyrazole Derivatives Which Modulate Human Serotonin Receptors. |
Abstract |
Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds (I) which act at the 5HT2A receptors. This new class encompasses the candidate compounds. In Formula (A) W is F, Cl, Br, I, C1-8 straight chain or branched alkyl, C3-8 cycloalkyl, C4-9 alkylcycloalkyl, or C2-8 alkenyl; X is O or S or NR2; Y is NR3R4, or (CH)mR5, or O(CH)nR6; m is an integer between 0 and 4, inclusive; n is an integer between 0 and 4, inclusive; Z is H, C-8 straight chain or branched alkyl, C3-8 cycloalkyl, C4-9 alkylcycloalkyl, or C2-8 alkenyl; R1, R2, R3 and R10are as defined in the application. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
United States Patent and Trademark Office (USPTO) |
Patent ID |
US8618288 |
Title |
Pyrimidine Compounds As Serotonin Receptor Modulators. |
Applicant(s) |
Janssen Pharmaceutica Nv |
Representative Drug(s) |
D00YGY |
Drug Info
|
Ki = 0.55 nM |
Click to Show More |
[2] |
2
|
D0B7NS
|
Drug Info
|
Ki = 4 nM
|
[2] |
3
|
D0P9VX
|
Drug Info
|
Ki = 4 nM
|
[2] |
4
|
D0U9UH
|
Drug Info
|
Ki = 11 nM
|
[2] |
5
|
D08DJY
|
Drug Info
|
Ki = 12.5 nM
|
[2] |
6
|
D0N2VA
|
Drug Info
|
Ki = 25 nM
|
[2] |
7
|
D0SE9K
|
Drug Info
|
Ki = 25 nM
|
[2] |
Patent ID |
US7858630 |
Title |
Serotonin 5-Ht2A and Dopamine D3 Receptors ModuLators, Useful In The Treatment of Cognitive Disorders, Drug Addiction, Depression, Anxiety, Dementia and Psychological Disorders. |
Applicant(s) |
Hoffmann-La Roche Inc |
Representative Drug(s) |
D06RIO |
Drug Info
|
Ki = 4.88 nM |
Click to Show More |
[2] |
2
|
D02GTU
|
Drug Info
|
Ki = 6 nM
|
[2] |
3
|
D0J7SD
|
Drug Info
|
Ki = 8.65 nM
|
[2] |
4
|
D0FR1P
|
Drug Info
|
Ki = 34 nM
|
[2] |
Patent ID |
US20090186895 |
Title |
Ethers, Secondary Amines and Derivatives Thereof As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Treatment of Disorders Related Thereto. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0H5XC |
Drug Info
|
IC50(DOI binding assay) = 0.025 nM |
Click to Show More |
[2] |
2
|
D0AQ1T
|
Drug Info
|
IC50(DOI binding assay) = 0.082 nM
|
[2] |
3
|
D0N8PF
|
Drug Info
|
IC50(DOI binding assay) = 0.26 nM
|
[2] |
4
|
D0KM0T
|
Drug Info
|
IC50(DOI binding assay) = 0.51 nM
|
[2] |
5
|
D0R6HF
|
Drug Info
|
IC50(DOI binding assay) = 1 nM
|
[2] |
6
|
D00PLP
|
Drug Info
|
IC50(DOI binding assay) = 1.2 nM
|
[2] |
7
|
D09WFK
|
Drug Info
|
IC50(DOI binding assay) = 4.4 nM
|
[2] |
Patent ID |
US20060229335 |
Title |
Diarylamine and Arylheteroarylamine Pyrazole Derivatives As Modulators of 5Ht2A. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0O3BR |
Drug Info
|
IC50(IP accumulation assay) = 1.77 nM |
Click to Show More |
[2] |
2
|
D0WC8M
|
Drug Info
|
IC50(IP accumulation assay) = 2.99 nM
|
[2] |
3
|
D0OR4G
|
Drug Info
|
IC50(IP accumulation assay) = 7 nM
|
[2] |
Patent ID |
US20160096811 |
Title |
Benzoisothiazole Compounds and Use In Preparation of Antipsychotic Drugs. |
Representative Drug(s) |
D0Z9WY |
Drug Info
|
Ki = 0.058 nM |
Click to Show More |
[1] |
2
|
D0M1UF
|
Drug Info
|
Ki = 0.23 nM
|
[1] |
Patent ID |
US8785441 |
Title |
3-Phenyl-Pyrazole Derivatives As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Treatment of Disorders Related Thereto. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Representative Drug(s) |
D0HY3K |
Drug Info
|
N.A. |
[2] |
Patent ID |
US8148417 |
Title |
Primary Amines and Derivatives Thereof As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Treatment of Disorders Related Thereto. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
Patent ID |
US7884101 |
Title |
3-Phenyl-Pyrazole Derivatives As Modulators of The 5-Ht2A Serotonin Receptor Useful for The Treatment of Disorders Related Thereto. |
Applicant(s) |
Arena Pharmaceuticals, Inc |
European Patent Office (EPO) |
Patent ID |
EP0638073 |
Title |
1-Piperazino-1,2-Dihydroindene Derivatives. |
Applicant(s) |
H. Lundbeck A / S |
Representative Drug(s) |
D0J4AZ |
Drug Info
|
Ki = 4.2 nM |
[2] |